Latest News for: endo

Edit

Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026

Norfolk Daily News 16 Jun 2026
Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical ... .
Edit

Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and ...

Missoulian 16 Jun 2026
Participants who resumed VYKAT XR following a 16-week ...
Edit

Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete

Caledonian Record 16 Jun 2026
– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect – ....
Edit

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting

PR Newswire 16 Jun 2026
The data were featured in an oral presentation at ENDO 2026, the Endocrine Society's Annual Meeting (Chicago, USA). The selection of MHB018A for oral presentation at ENDO 2026 underscores the ...
Edit

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026

PR Newswire 16 Jun 2026
BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago.
Edit

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough

Caledonian Record 15 Jun 2026
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 ....
Edit

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class ...

Nasdaq Globe Newswire 15 Jun 2026
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 ... .
Edit

Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of ...

Nasdaq Globe Newswire 15 Jun 2026
– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect – ... .
Edit

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Nasdaq Globe Newswire 15 Jun 2026
... preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting.
Edit

ENDO 2026: Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants With Uncontrolled Hypertension (Mineralys Therapeutics Inc)

Public Technologies 15 Jun 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 132457705) .
Edit

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 (Opko Health Inc)

Public Technologies 15 Jun 2026
) אופקו הלת', אינק. OPKO HEALTH, INC. Corporation no. 2279206. Israel Securities Authority Tel Aviv Stock Exchange C002 ( Public ) Reported via MAGNA. 15/06/2026. www.isa.gov.il www.tase.co.il Reference. 2026-02-056447. Immediate Report ... Address.
Edit

Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026

PR Newswire 15 Jun 2026
Data featured in oral presentation at ENDO 2026 show that dual MC3R/MC4R activation drives weight loss, limits rebound, and preserves lean mass in obese nonhuman primates ... (ENDO 2026) in Chicago, IL.
Edit

Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

PR Newswire 15 Jun 2026
At ENDO 2026, ... Oral presentation at ENDO 2026; 14 June 2026 ... https.//news.cision.com/h--lundbeck-a-s/r/lundbeck-presents-new-phase-ii-asedebart-data-in-cushing-s-disease-at-endo-2026,c4362170.
Edit

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

PR Newswire 15 Jun 2026
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq ... These data were presented at the Endocrine Society's annual meeting, ENDO 2026, in Chicago ... Presentations at the ENDO 2026 annual meeting included. ... Title ... Title ... Title ... .
Edit

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 (Form 8-K) (Rhythm Pharmaceuticals Inc)

Public Technologies 15 Jun 2026
) Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 ... Annual Meeting (ENDO 2026) in Chicago.

Article Search

tools
×
×
×
×